ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2401

Identification and Characterization of Two Osteoarthritis Phenotypes Applying Two Clinically Tested Biomarkers

Anne C. Bay-Jensen1, Asger Bihlet2, Inger Byrjalsen3, Bente J. Riis2, Claus Christiansen2, Morten Asser Karsdal1 and Jeppe Andersen2, 1Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience, Herlev, Denmark, 3Research & Development, Nordic Bioscience, Herlev, Denmark

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, osteoarthritis and phenotypes

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Session Title: Osteoarthritis - Clinical Aspects Poster II: Biomarkers, Biomechanics and Health Services Research

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The osteoarthritis (OA) population is heterogeneous and it is therefore difficult to target all patients with the same intervention. Thus there is a clinical need for diagnostic tools, which can aid in identification of patients of different phenotypes. Urinary CTX-II is a biomarker of cartilage degradation, which previously have been associated with disease severity. Serum C3M is a biomarker of type II collagen remodeling, which is released from the synovial membrane when induced with pro-inflammatory cytokines. We hypothesize that patients with low cartilage degradation (low CTX-II), but a high synovial turnover (high C3M) have a synovial-driven OA, whereas patients with a high level of cartilage degradation and a low level of synovial turnover have a cartilage-driven phenotype, and that these phenotypes are markedly different. The aim of the study was to compare these two phenotypes on clinical parameters and thereby test above hypothesis.

Methods: CTX-II and C3M were measured in the urine/serum of knee OA patients (n=497) from the placebo arms of the two phase III RCTs (NCT00486434 and NCT00704847). Baseline pain questionnaires (WOMAC), as well as radiography and MRI of both knees (target (T), non-target (NT)) were recorded for each patient. Biomarker cut-offs were determined at the 75%-quartile limit. The synovial phenotype (n=89) was defined as having C3M levels above 7.3ng/mL and CTX-II levels below or equal to 345pmol/mL (creatinine corrected). The cartilage phenotype (n=99) was defined as the inverse. Difference between clinical measures and biomarkers in the two patient groups were analyzed by Mann-Whitney.

Results: There were no difference in age and BMI, nor gender distribution, in the two phenotype groups. Joint space width were significantly lower in both knees the cartilage phenotype (NT, p=0.0083; T p=0.042). The sum of Kellgren-Lawrence score was significant higher in the cartilage phenotype (p=0.0001). This corresponded to a significantly higher cartilage volume in the synovial phenotype (NT, p=0.0026; T, p=0.046). Interestingly, WOMAC pain was significantly higher in the cartilage-driven phenotype as compared to the synovial phenotype (NT, p=0.045; T, p=0.014).

Conclusion: We found the two phenotypes, defined by two biomarkers reflecting synovial and cartilage turnover, respectively, where significantly different when comparing standard clinical measures. This may indicate that non-invasive biomarkers may aid in the identification of patient phenotypes and thereby, in the future, aid in guiding treatment of patients.


Disclosure: A. C. Bay-Jensen, Nordic Bioscience Diagnostic, 1,Nordic Bioscience Diagnostic, 3; A. Bihlet, Nordic Bioscience Diagnostic, 3; I. Byrjalsen, Nordic Bioscience Diagnostic, 3; B. J. Riis, Nordic Bioscience Diagnostic, 4; C. Christiansen, Nordic Bioscience Diagnostic, 4; M. A. Karsdal, Nordic Bioscience Diagnostic, 1,Nordic Bioscience Diagnostic, 3; J. Andersen, Nordic Bioscience Diagnostic, 3.

To cite this abstract in AMA style:

Bay-Jensen AC, Bihlet A, Byrjalsen I, Riis BJ, Christiansen C, Karsdal MA, Andersen J. Identification and Characterization of Two Osteoarthritis Phenotypes Applying Two Clinically Tested Biomarkers [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/identification-and-characterization-of-two-osteoarthritis-phenotypes-applying-two-clinically-tested-biomarkers/. Accessed May 26, 2022.
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-and-characterization-of-two-osteoarthritis-phenotypes-applying-two-clinically-tested-biomarkers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.